Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

653

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: SUN-101 50 mcg BID eFlow (CS) nebulizer
DRUG: SUN-101 25 mcg BID eFlow (CS) nebulizer
DRUG: Placebo BID eFlow Closed System (CS) nebulizer

Sponsor

Sunovion Respiratory Development Inc.